Chambers J, Park J, Cronk D, Chapman C, Kennedy F R, Wilson S, Milligan G
SB Pharmaceuticals, Pinnacles, Harlow, U.K.
Biochem J. 1994 Nov 1;303 ( Pt 3)(Pt 3):973-8. doi: 10.1042/bj3030973.
Chinese hamster ovary (CHO) cells transfected to express human beta 2- or beta 3-adrenoceptors (beta 2-CHO and beta 3-CHO cells) were exposed to the beta-adrenoceptor agonist isoprenaline at various concentrations and for differing times. Sustained exposure of the beta 2-CHO but not beta 3-CHO cells to isoprenaline resulted in a time- and concentration-dependent down-regulation of the receptor as measured by a reduction in specific binding of [125I]cyanopindolol. Such maintained exposure of cells expressing either receptor to the agonist produced a marked down-regulation of immunologically detectable levels of the alpha subunit of the stimulatory guanine-nucleotide-binding protein Gs. This effect was specific for Gs because levels of both G12 alpha and Gq alpha/G11 alpha were unaltered by isoprenaline treatment of both beta 2-CHO and beta 3-CHO cells. The effect of isoprenaline on Gs alpha down-regulation was some 30-fold more potent in the beta 2-CHO than in the beta 3-CHO cells. Time courses of isoprenaline-induced down-regulation of Gs alpha were not different, however, in the two cell lines. Isoprenaline treatment of the beta 3-CHO cells produced a desensitization of agonist-mediated regulation of adenylyl cyclase, manifested by a 4-fold reduction in the potency and a 30% reduction in maximal effect of the agonist, whereas desensitization of the beta 2-CHO cells was considerably greater (25-fold reduction in potency and 70% reduction in maximal effect). These results demonstrate that agonist-induced down-regulation of the G-protein which interacts with a receptor can be produced by both beta 2- and beta 3-adrenoceptors. Despite apparent concurrence of down-regulation of receptors and G-proteins in other systems [e.g. Adie, Mullaney, McKenzie and Milligan (1992) Biochem. J. 285, 529-536], agonist-induced receptor down-regulation does not appear to be a prerequisite for down-regulation of the G-protein. Furthermore, the results suggest that agonist-induced down-regulation of a G-protein may be sufficient, in the absence of receptor regulation, to induce some agonist desensitization of effector function.
将转染以表达人β2-或β3-肾上腺素能受体(β2-CHO细胞和β3-CHO细胞)的中国仓鼠卵巢(CHO)细胞暴露于不同浓度和不同时间的β-肾上腺素能受体激动剂异丙肾上腺素。持续将β2-CHO细胞而非β3-CHO细胞暴露于异丙肾上腺素,会导致受体出现时间和浓度依赖性下调,这通过[125I]氰胍心安特异性结合的减少来衡量。将表达任一受体的细胞持续暴露于激动剂会使刺激性鸟嘌呤核苷酸结合蛋白Gs的α亚基的免疫可检测水平显著下调。这种效应对Gs具有特异性,因为β2-CHO细胞和β3-CHO细胞经异丙肾上腺素处理后,G12α和Gqα/G11α的水平均未改变。异丙肾上腺素对Gsα下调的作用在β2-CHO细胞中比在β3-CHO细胞中强约30倍。然而,在这两种细胞系中,异丙肾上腺素诱导的Gsα下调的时间进程并无差异。用异丙肾上腺素处理β3-CHO细胞会导致激动剂介导的腺苷酸环化酶调节脱敏,表现为激动剂效力降低4倍,最大效应降低30%,而β2-CHO细胞的脱敏程度要大得多(效力降低25倍,最大效应降低70%)。这些结果表明,激动剂诱导的与受体相互作用的G蛋白下调可由β2-和β3-肾上腺素能受体产生。尽管在其他系统中受体和G蛋白的下调明显同时发生[例如Adie、Mullaney、McKenzie和Milligan(1992年)《生物化学杂志》285,529 - 536],但激动剂诱导的受体下调似乎并非G蛋白下调的先决条件。此外,结果表明,在不存在受体调节的情况下,激动剂诱导的G蛋白下调可能足以诱导效应器功能的某种激动剂脱敏。